Movatterモバイル変換

[0]ホーム
URL:

Jump to content
WikipediaThe Free Encyclopedia
Search

Defactinib

From Wikipedia, the free encyclopedia
Pharmaceutical

Pharmaceutical compound
Defactinib
Clinical data
Other namesPF-04554878, VS-6063
Identifiers
  • N-methyl-4-[[4-[[3-[methyl(methylsulfonyl)amino]pyrazin-2-yl]methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]benzamide
CAS Number
PubChemCID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
PDB ligand
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC20H21F3N8O3S
Molar mass510.50 g·mol−1
3D model (JSmol)
  • CNC(=O)C1=CC=C(C=C1)NC2=NC=C(C(=N2)NCC3=NC=CN=C3N(C)S(=O)(=O)C)C(F)(F)F
  • InChI=1S/C20H21F3N8O3S/c1-24-18(32)12-4-6-13(7-5-12)29-19-28-10-14(20(21,22)23)16(30-19)27-11-15-17(26-9-8-25-15)31(2)35(3,33)34/h4-10H,11H2,1-3H3,(H,24,32)(H2,27,28,29,30)
  • Key:FWLMVFUGMHIOAA-UHFFFAOYSA-N

Defactinib (INN, codenamedVS-6063) is aninhibitor ofPTK2, also known as focal adhesion kinase (FAK),Pyk2, andMELK which was developed byPfizer and licensed toVerastem Oncology as a potential treatment forsolid tumors.

Development formesothelioma was discontinued in 2015 due to lack of efficacy in a placebo-controlled phase II trial.[1][2] Subsequent research in patients with specificNF2 mutations also found limited activity.[3]

The co-packaged medicationavutometinib/defactinib was approved for medical use in the United States in May 2025.[4][5]

References

[edit]
  1. ^Nathan VL (28 September 2015)."Verastem stops cancer therapy development; shares plunge" (Press release). Reuters. Retrieved5 June 2022.
  2. ^Fennell DA, Baas P, Taylor P, Nowak AK, Gilligan D, Nakano T, et al. (April 2019). "Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study".Journal of Clinical Oncology.37 (10):790–798.doi:10.1200/JCO.2018.79.0543.PMID 30785827.S2CID 73478275.
  3. ^Jackman DM, Jegede O, Zauderer MG, Mitchell EP, Zwiebel J, Gray RJ, et al. (20 May 2021). "A phase 2 study of defactinib (VS-6063) in patients with NF2 altered tumors: Results from NCI-match (EAY131) subprotocol U.".Journal of Clinical Oncology.39 (15_suppl). American Society of Clinical Oncology (ASCO): 3087.doi:10.1200/jco.2021.39.15_suppl.3087.ISSN 0732-183X.S2CID 236401789.
  4. ^"FDA grants accelerated approval to the combination of avutometinib and defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer".U.S.Food and Drug Administration. 8 May 2025. Archived fromthe original on 8 May 2025. Retrieved16 May 2025.Public Domain This article incorporates text from this source, which is in thepublic domain.
  5. ^"FDA Approves the Avmapki Fakzynja Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer".Verastem (Press release). Retrieved16 May 2025.


Stub icon

Thisantineoplastic orimmunomodulatorydrug article is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Defactinib&oldid=1292956410"
Categories:
Hidden categories:
[8]ページ先頭
©2009-2025 Movatter.jp